KR970064607A - 암을 예방 및 치료하기 위한 알파_1-아드레날린성수용체 길항물질의 용도 - Google Patents

암을 예방 및 치료하기 위한 알파_1-아드레날린성수용체 길항물질의 용도 Download PDF

Info

Publication number
KR970064607A
KR970064607A KR1019970010501A KR19970010501A KR970064607A KR 970064607 A KR970064607 A KR 970064607A KR 1019970010501 A KR1019970010501 A KR 1019970010501A KR 19970010501 A KR19970010501 A KR 19970010501A KR 970064607 A KR970064607 A KR 970064607A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
adrenergic receptor
medicament
receptor antagonist
composition according
Prior art date
Application number
KR1019970010501A
Other languages
English (en)
Inventor
티모씨 씨 톰슨
마이클 지 와일리
구앙 양
Original Assignee
스피겔 알렌 제이
화이자 인코포레이티드
크로커 사무엘 에스
베일러 칼리지 오브 메디신
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스피겔 알렌 제이, 화이자 인코포레이티드, 크로커 사무엘 에스, 베일러 칼리지 오브 메디신 filed Critical 스피겔 알렌 제이
Publication of KR970064607A publication Critical patent/KR970064607A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명은 암을 치료 또는 예방하기에 유효한 α1-아드레날린성수용체 길항물질 또는 그의 약학적으로 허용가능한 산 부가 염을 포함한 일정량의 약제를 포함하는 약학 조성물, 및 이 조성물을 상기 포유동물에게 부여하는 것을 포함하는, 포유동물의 암을 치료 또는 예방하기 위한 방법에 관한 것이다.

Description

암을 예방 또는 치료하기 위한 알파1-아드레날린성수용체 길항물질의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 암을 치료 또는 예방하기에 유효한 α1-아드레날린성수용체 길항물질 또는 그의 약학적으로 허용가능한 산 부가 염을 포함한 일정량의 약제를 포함하는, 매일 투여하여 포유동물의 암을 치료 또는 예방하기 위한 약학 조성물.
  2. 제1항에 있어서, 상기 α1-아드레날린성수용체 길항물질이 알푸조신, 인도라민, 테트라조신, 부나조신, 독사조신 및 그의 6'- 및 7'-하이독시 대사물질, 프라조신, 탐설로신, 아바노퀼, 레코르다티(Recordati) 15/2739(상표명), RS 17053(상표명) 및 SL 89.0591(상표명)로 이루어진 그룹에서 선택되는 약학 조성물.
  3. 제2항에 있어서, α1-아드레날린성수용체 길항물질이 독사조신 및 그의 6'- 및 7'-하이독시 대사물질, 및 프라조신 중에서 선택되는 약학조성물.
  4. 제3항에 있어서, α1-아드레날린성수용체 길항물질이 독사조신 및 그의 6'- 및 7'-하이독시 대사물질 중에서 선택되는 약학조성물.
  5. 제4항에 있어서, α1-아드레날린성수용체 길항물질이 독사조신의 6'-하이옥시 대사물질인 약학 조성물.
  6. 제4항에 있어서, α1-아드레날린성수용체 길항물질이 독사조신의 7'-하이옥시 대사물질인 약학 조성물.
  7. 제1항 내지 제6항 중 어느 한 항에 있어서, 상기 약제가 경구적으로 투여되는 형태인 약학 조성물.
  8. 제1항 내지 제6항 중 어느 한 항에 있어서, 상기 약제가 복강내 투여되는 형태인 약학 조성물.
  9. 제1항 내지 제6항 중 어느 한 항에 있어서, 상기 약제가 경피 투여되는 형태인 약학 조성물.
  10. 제1항 내지 제6항 중 어느 한 항에 있어서, 상기 약제가 비경구적으로 투여되는 형태인 약학 조성물.
  11. 제1항에 있어서, 하루에 수회 투여하기 위해 유효한 1일 투여량 미만의 약제를 포함하는 약학 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970010501A 1996-03-27 1997-03-26 암을 예방 및 치료하기 위한 알파_1-아드레날린성수용체 길항물질의 용도 KR970064607A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1422896P 1996-03-27 1996-03-27
US60/014,228 1996-03-27

Publications (1)

Publication Number Publication Date
KR970064607A true KR970064607A (ko) 1997-10-13

Family

ID=21764236

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970010501A KR970064607A (ko) 1996-03-27 1997-03-26 암을 예방 및 치료하기 위한 알파_1-아드레날린성수용체 길항물질의 용도

Country Status (16)

Country Link
US (1) US5935962A (ko)
EP (1) EP0799618B1 (ko)
JP (1) JPH10101579A (ko)
KR (1) KR970064607A (ko)
AT (1) ATE294582T1 (ko)
AU (1) AU733146B2 (ko)
CA (1) CA2201089A1 (ko)
DE (1) DE69733169T2 (ko)
DK (1) DK0799618T3 (ko)
ES (1) ES2242207T3 (ko)
HU (1) HUP9700661A3 (ko)
IL (2) IL120303A0 (ko)
MY (1) MY126321A (ko)
NZ (1) NZ314488A (ko)
TW (1) TW504386B (ko)
ZA (1) ZA972601B (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000045550A2 (fr) * 1999-01-27 2000-08-03 France Telecom Procede destine a prouver l'authenticite d'une entite ou l'integrite d'un message au moyen d'un exposant public egal a une puissance de deux
EP1351675A2 (en) * 2000-08-24 2003-10-15 The Regents of the University of California Alpha-difluoromethylornithine (dfmo) use in the human prostate
EP1293198B1 (en) * 2001-09-14 2005-02-09 Schwarz Pharma Ag Device for transdermal administration for the treatment of urinary tract disorders
WO2006052409A2 (en) * 2004-10-23 2006-05-18 Case Western Reserve University Peptide and small molecule agonists of epha and their uses
WO2007109142A2 (en) * 2006-03-17 2007-09-27 Oregon Health & Science University M3 muscarinic receptor antagonists for treating tumors
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
US9554988B2 (en) 2010-06-30 2017-01-31 Galderma Research & Development Method for preventing or treating skin tumor
ES2585847T3 (es) 2010-06-30 2016-10-10 Galderma Research & Development Utilización de un agonista del receptor adrenérgico alfa para prevenir o tratar un tumor de la piel
US20120178757A1 (en) * 2010-12-09 2012-07-12 Nottingham University Hospitals Nhs Trust Method For The Prevention Of Cancer Metastasis
GR20200100456A (el) * 2020-08-03 2022-03-09 Inderes Ltd, Συνδυασμος φαρμακων και χρηση του στη θεραπεια του καρκινου

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
US4758569A (en) * 1987-08-26 1988-07-19 Pfizer Inc. Doxazosin as an anti-atherosclerosis agent
PT564093E (pt) * 1992-04-01 2000-04-28 Pfizer Metabolitos hidroxilados e derivados de doxazosina como agentes anti-aterosclerose
FR2694495B1 (fr) * 1992-08-05 1994-09-23 Synthelabo Préparation pharmaceutique transdermique contenant de l'alfuzosine.
US5578611A (en) * 1992-11-13 1996-11-26 Synaptic Pharmaceutical Corporation Use of α-1C specific compounds to treat benign prostatic hyperplasia
US5503843A (en) * 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents

Also Published As

Publication number Publication date
AU733146B2 (en) 2001-05-10
CA2201089A1 (en) 1997-09-27
EP0799618A3 (en) 1997-11-12
MY126321A (en) 2006-09-29
IL120495A0 (en) 1997-07-13
EP0799618A2 (en) 1997-10-08
DE69733169D1 (de) 2005-06-09
ZA972601B (en) 1998-09-28
ATE294582T1 (de) 2005-05-15
HU9700661D0 (en) 1997-05-28
DE69733169T2 (de) 2006-01-19
NZ314488A (en) 2000-09-29
IL120303A0 (en) 1997-06-10
US5935962A (en) 1999-08-10
HUP9700661A2 (hu) 1998-11-30
EP0799618B1 (en) 2005-05-04
HUP9700661A3 (en) 1999-06-28
JPH10101579A (ja) 1998-04-21
TW504386B (en) 2002-10-01
AU1656997A (en) 1997-10-02
DK0799618T3 (da) 2005-05-30
ES2242207T3 (es) 2005-11-01
IL120495A (en) 2004-09-27

Similar Documents

Publication Publication Date Title
DK0850046T3 (da) Mikroemulsioner til anvendelse som vhikel til indgift af active forbindelser
BR0109150A (pt) Método para administração de um anestésico local a um indivìduo em necessidade de um efeito anestésico local, emplastro, composição, e, recipiente
NO993979L (no) FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor
ATE323491T1 (de) Peroral zu verabreichende arzneiform enthaltend eine kombination von einem opioid agonisten und naltrexon
ATE301994T1 (de) Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda- antagonist
ATE293458T1 (de) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
DK0696280T3 (da) Substituerede pyrrolidin-3-yl-alkyl-piperidiner anvendelige som tachykinin-antagonister
KR970064607A (ko) 암을 예방 및 치료하기 위한 알파_1-아드레날린성수용체 길항물질의 용도
NO981944D0 (no) Lipopolyaminer som transfeksjonsmidler samt farmas÷ytisk anvendelse derav
KR950702409A (ko) 방출 조절 모르핀 제제(controlled release morphine preparation)
BR9911046A (pt) Uso de antidepressivos tricìclicos para analgesia local
TR199901669T2 (xx) Erkeklerdeki ereksiyon probleminin tedavisi i�in gerekli dozaj �ekilleri ve metod.
EA200100870A1 (ru) Композиции-ингибиторы циклооксигеназы-2 с быстро наступающим терапевтическим действием
KR960700061A (ko) 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence)
HUP0400475A2 (hu) Egy AT1 receptor antagonista vagy egy ACE inhibitor vagy egy HMG-CO-A reduktáz inhibitor közül legalább két vegyület kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk
BRPI0412557A (pt) forma de dosagem farmacêutica de eventos cardiovasculares
KR970701544A (ko) 5-HT_2 길항제를 사용하는 강박반응의 치료법(Treatment of obsessive-compulsive disorders with 5-HT_2 antagonists)
EA200300183A1 (ru) Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
SE9602442D0 (sv) Administration of pharmaceuticals
ES2189252T3 (es) Composiciones analgesicas que comprenden un antagonista de la colecistoquinina y un opioide.
HUP9700660A2 (hu) Alfa1-adrenoreceptor antagonisták felhasználása a prosztata jóindulatú hyperpláziájának megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
Mercadante Methadone in cancer pain
ATE241349T1 (de) Pharmazeutische zusammensetzung enthaltend eine kombination der dextro- und laevo-isomeren von sotalol
NO944214L (no) Farmasöytiske preparater for rektal administrering, inneholdende alkylsulfonamider som er HT1-agonister

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application